Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Methotrexate attenuates vascular inflammation through an adenosine-microRNA dependent pathway

ABSTRACT: We report transcriptomic changes in white adipose tissue of systemic miR-181a2b2 KO mice in response to high fat diet and methotrexate.

ORGANISM(S): Mus musculus

PROVIDER: GSE164251 | GEO | 2021/01/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Methotrexate attenuates vascular inflammation through an adenosine-microRNA dependent pathway

Project description:Methotrexate attenuates vascular inflammation through an adenosine-microRNA dependent pathway

| PRJNA689719 | ENA

Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway.

Project description: Not available

| S-EPMC7840179 | biostudies-literature

Methotrexate Clearance

Project description:Methotrexate Clearance

| PRJNA76037 | ENA

Caco2 response to methotrexate, lactoferrin, and methotrexate-lactoferrin co-exposure

Project description:bulk sequencing outputs of Caco2 cells after exposure to permeability modifying and permeability rescuing agents. To identify the molecular drivers for methotrexate-induced barrier dysfunction, we conducted RNA sequencing on Caco2 spheroids treated with methotrexate and lactoferrin. Given our observation that barrier function was compromised as early as 4-6 hours after exposure to methotrexate, we isolated RNA from spheroids 4-hour post-treatment to capture the transcriptional events responsible for initiating the processes.

2020-01-10 | GSE140066 | GEO

Methotrexate activates aspects of inflammation in EA.hy 926 cells

Project description:Methotrexate (MTX) is an anti-folate drug used to treat inflammatory diseases such as rheumatoid arthritis. The changes induced by MTX were profiled within EA.hy 926 cells grown in normal (Hi) and low (Lo) folate. Several inflammatory genes were up regulated and several mitosis related genes were down regulated.

2012-09-30 | GSE32008 | GEO

Caco2 response to methotrexate, lactoferrin, and methotrexate-lactoferrin co-exposure

Project description:Caco2 response to methotrexate, lactoferrin, and methotrexate-lactoferrin co-exposure

| PRJNA588171 | ENA

Methotrexate activates aspects of inflammation in EA.hy 926 cells

2012-09-30 | E-GEOD-32008 | biostudies-arrayexpress

Dauricine Attenuates Vascular Endothelial Inflammation Through Inhibiting NF-κB Pathway.

Project description: Not available

| S-EPMC8672219 | biostudies-literature

Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model

Project description:Drug repurposing is a fast and effective way to develop drugs for an emerging disease such as COVID-19. The main challenges of effective drug repurposing are the discoveries of the right therapeutic targets and the right drugs for combating the disease. Here, we present a systematic repurposing approach, combining Homopharma and hierarchal systems biology networks (HiSBiN), to predict 327 therapeutic targets and 21,233 drug-target interactions of 1,592 FDA drugs for COVID-19. Among these multi-target drugs, eight candidates (along with pimozide and valsartan) were tested and methotrexate was identified to affect 14 therapeutic targets suppressing SARS-CoV-2 entry, viral replication, and COVID-19 pathologies. Through the use of in vitro (EC50 = 0.4 uM) and in vivo models, we show that methotrexate is able to inhibit COVID-19 via multiple mechanisms. Our in vitro studies illustrate that methotrexate can suppress SARS-CoV-2 entry and replication by targeting furin and DHFR of the host, respectively. Additionally, methotrexate inhibits all four SARS-CoV-2 variants of concern. In a Syrian hamster model for COVID-19, methotrexate reduced virus replication, inflammation in the infected lungs. By analysis of transcriptomic analysis of collected samples from hamster lung, we uncovered that neutrophil infiltration and the pathways of innate immune response, adaptive immune response and thrombosis are modulated in the treated animals. We demonstrate that this systematic repurposing approach is potentially useful to identify pharmaceutical targets, multi-target drugs and regulated pathways for a complex disease. Our findings indicate that methotrexate is established as a promising drug against SARS-CoV-2 variants and can be used to treat lung damage and inflammation in COVID-19, warranting future evaluation in clinical trials.

2022-12-13 | GSE179709 | GEO

Methotrexate resistant Leishmania strains

Project description:This SuperSeries is composed of the following subset Series: GSE9947: Transcriptional analysis of Leishmania infantum methotrexate resistant strains using full-genome DNA microarrays GSE9948: Transcriptional analysis of Leishmania major methotrexate resistant strains using full-genome DNA microarrays Keywords: SuperSeries Refer to individual Series

2010-05-25 | E-GEOD-9949 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data